BASKHANBIOPharma Inc.
KKRX:3543903,555.00
KRW
-40.00
(-1.11%)
ISIN
KR7354390007
Return %
Stock
S&P 500
1Y
-30.57
13.14
3Y
-52.15
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Beop-Pyo Lee
- Full Time Employees
- 114
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Anseong-si South Korea
- IPO Date
- Jul 20, 2022
- Website
- baskhanbio.com
- Similar Companies
- Business
- BASKHANBIOPharma Inc. is a South Korea-based biopharmaceutical and healthcare company primarily engaged in the research, development, manufacturing, and distribution of pharmaceuticals, health functional foods, and specialized healthcare solutions. The company operates through core business segments comprising prescription pharmaceuticals (ETC), over-the-counter (OTC) medications, dietary supplements, and third-party contract manufacturing. Its product and service portfolio includes cardiovascular and circulatory system treatments; metabolic disorder therapies; gastrointestinal agents; central nervous system and neurological medications; musculoskeletal, analgesic, and anti-inflammatory drugs; respiratory and anti-infective formulations; health functional foods and dietary supplements designed for immune health, gut vitality, and nutritional support; specialized cosmeceutical and dermatological products; and comprehensive OEM, ODM, and contract development and manufacturing organization (CDMO) services. BASKHANBIOPharma markets and supplies its offerings to hospitals, specialty clinics, retail pharmacies, and healthcare distributors across South Korea and select international markets. In recent strategic developments, the company executed a corporate rebranding and reorganization to BASKHANBIOPharma Inc. to accelerate its expansion into advanced biopharmaceuticals and integrated healthcare products. Furthermore, the company upgraded its Good Manufacturing Practice (GMP)-certified production facilities to increase contract manufacturing capacity, entered into domestic co-promotion and distribution agreements to broaden market access, and initiated new development programs focused on enhanced drug delivery technologies and high-potency functional nutrition formulations. BASKHANBIOPharma Inc. was founded in 2019 and is headquartered in Seoul, South Korea.